Organogenesis
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 862
- Market Cap
- -
- Introduction
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Other: Standard of CareDevice: PuraPly AMDevice: PuraPly XT
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 170
- Registration Number
- NCT06618612
- Locations
- 🇺🇸
Kent State University, College of Podiatric Medicine, Clevland, Ohio, United States
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 474
- Registration Number
- NCT06000410
- Locations
- 🇺🇸
Central Research Associates, Inc., Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Fiel Family & Sports Medicine, Tempe, Arizona, United States
Clinical Study Of Affinity Versus SOC In The Management Of VLUs
- Conditions
- Venous Leg Ulcer
- Interventions
- Other: Affinity
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 200
- Registration Number
- NCT04901013
- Locations
- 🇺🇸
ILD Research, Carlsbad, California, United States
Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 474
- Registration Number
- NCT04636229
- Locations
- 🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸AMR Mobile, Mobile, Alabama, United States
Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Other: NuShield
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 200
- Registration Number
- NCT03855514
- Locations
- 🇺🇸
ILD Research Center, Carlsbad, California, United States
🇺🇸Limb Preservation Platform, Fresno, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
- Conditions
- Chronic Pressure Ulcers
- Interventions
- Device: PuraPly® Antimicrobial Wound MatrixOther: SOC for Pressure Ulcers
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 40
- Registration Number
- NCT03502824
- Locations
- 🇺🇸
Northwell Health, Lake Success, New York, United States
🇺🇸NYU Winthrop Hospital, Mineola, New York, United States
The RESPOND Registry
- Conditions
- Draining WoundsPartial Thickness WoundDiabetic UlcerTrauma WoundsPressure UlcerVenous UlcerSurgical WoundsChronic Vascular Ulcer
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 310
- Registration Number
- NCT03286452
- Locations
- 🇺🇸
Advanced Wound Care Center at Yavapai Regional Medical Center, Prescott Valley, Arizona, United States
🇺🇸Jupiter Medical Center, Jupiter, Florida, United States
🇺🇸West Gables Rehab Hospital, Miami, Florida, United States
Affinity Prospective Diabetic Foot Trial Crossover Group
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Other: Affinity human amniotic membrane
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 20
- Registration Number
- NCT03205436
- Locations
- 🇺🇸
GF Professional Research, Miami Lakes, Florida, United States
🇺🇸Barry University Clinical Research, North Miami Beach, Florida, United States
🇺🇸The Foot and Ankle Wellness Center, Ford City, Pennsylvania, United States
Prospective PuraPly™ AM Case Series Study
- Conditions
- Venous UlcersDiabetic UlcersTrauma WoundsSurgical WoundsPressure Ulcers
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 43
- Registration Number
- NCT03070925
- Locations
- 🇺🇸
Northwell Health, Inc, Lake Success, New York, United States
PuraPly™ Antimicrobial Wound Matrix and Wound Management
- Conditions
- Diabetic UlcerVenous UlcerTrauma WoundPressure UlcerSurgical Wound
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 100
- Registration Number
- NCT03070938
- Locations
- 🇺🇸
Winthrop University Hospital, Mineola, New York, United States